These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
290 related items for PubMed ID: 23341242
1. The four and a half LIM-domain 2 controls early cardiac cell commitment and expansion via regulating β-catenin-dependent transcription. Renger A, Zafiriou MP, Noack C, Pavlova E, Becker A, Sharkova K, Bergmann MW, El-Armouche A, Zimmermann WH, Zelarayán LC. Stem Cells; 2013 May; 31(5):928-40. PubMed ID: 23341242 [Abstract] [Full Text] [Related]
2. FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression. Hamidouche Z, Haÿ E, Vaudin P, Charbord P, Schüle R, Marie PJ, Fromigué O. FASEB J; 2008 Nov; 22(11):3813-22. PubMed ID: 18653765 [Abstract] [Full Text] [Related]
3. Wnt/β-catenin and Bmp signals control distinct sets of transcription factors in cardiac progenitor cells. Klaus A, Müller M, Schulz H, Saga Y, Martin JF, Birchmeier W. Proc Natl Acad Sci U S A; 2012 Jul 03; 109(27):10921-6. PubMed ID: 22711842 [Abstract] [Full Text] [Related]
4. Deletion of FHL2 in fibroblasts attenuates fibroblasts activation and kidney fibrosis via restraining TGF-β1-induced Wnt/β-catenin signaling. Duan Y, Qiu Y, Huang X, Dai C, Yang J, He W. J Mol Med (Berl); 2020 Feb 03; 98(2):291-307. PubMed ID: 31927599 [Abstract] [Full Text] [Related]
6. Four and a half LIM domains 2 contributes to the development of human tongue squamous cell carcinoma. Wang Q, Wang X, Tian X, Tang R, Xu X. J Mol Histol; 2016 Apr 03; 47(2):105-16. PubMed ID: 26759260 [Abstract] [Full Text] [Related]
9. The LIM-only protein FHL2 controls mesenchymal cell osteogenic differentiation and bone formation through Wnt5a and Wnt10b. Brun J, Fromigué O, Dieudonné FX, Marty C, Chen J, Dahan J, Wei Y, Marie PJ. Bone; 2013 Mar 03; 53(1):6-12. PubMed ID: 23201222 [Abstract] [Full Text] [Related]
10. FHL2 participates in renal interstitial fibrosis by altering the phenotype of renal tubular epithelial cells via regulating the β-catenin pathway. Zhou SG, Ma HJ, Guo ZY, Zhang W, Yang X. Eur Rev Med Pharmacol Sci; 2018 May 03; 22(9):2734-2741. PubMed ID: 29771425 [Abstract] [Full Text] [Related]
13. FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo. Brun J, Dieudonné FX, Marty C, Müller J, Schüle R, Patiño-García A, Lecanda F, Fromigué O, Marie PJ. PLoS One; 2013 Oct 01; 8(1):e55034. PubMed ID: 23383046 [Abstract] [Full Text] [Related]
14. Identification of the LIM protein FHL2 as a coactivator of beta-catenin. Wei Y, Renard CA, Labalette C, Wu Y, Lévy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia MA. J Biol Chem; 2003 Feb 14; 278(7):5188-94. PubMed ID: 12466281 [Abstract] [Full Text] [Related]
16. The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. Martin B, Schneider R, Janetzky S, Waibler Z, Pandur P, Kühl M, Behrens J, von der Mark K, Starzinski-Powitz A, Wixler V. J Cell Biol; 2002 Oct 14; 159(1):113-22. PubMed ID: 12370240 [Abstract] [Full Text] [Related]
17. A regulatory pathway involving Notch1/beta-catenin/Isl1 determines cardiac progenitor cell fate. Kwon C, Qian L, Cheng P, Nigam V, Arnold J, Srivastava D. Nat Cell Biol; 2009 Aug 14; 11(8):951-7. PubMed ID: 19620969 [Abstract] [Full Text] [Related]
18. The LIM domain protein FHL2 interacts with the NR5A family of nuclear receptors and CREB to activate the inhibin-α subunit gene in ovarian granulosa cells. Matulis CK, Mayo KE. Mol Endocrinol; 2012 Aug 14; 26(8):1278-90. PubMed ID: 22734036 [Abstract] [Full Text] [Related]
19. Wnt/β-Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells. Månsson-Broberg A, Rodin S, Bulatovic I, Ibarra C, Löfling M, Genead R, Wärdell E, Felldin U, Granath C, Alici E, Le Blanc K, Smith CIE, Salašová A, Westgren M, Sundström E, Uhlén P, Arenas E, Sylvén C, Tryggvason K, Corbascio M, Simonson OE, Österholm C, Grinnemo KH. Stem Cell Reports; 2016 Apr 12; 6(4):607-617. PubMed ID: 27052314 [Abstract] [Full Text] [Related]